INTRODUCTION {#s1}
============

Transforming growth factor beta 1 (TGF-β1) is a polypeptide cytokine that belongs to the transforming growth factor beta super-family \[[@R1]\]. It is widely accepted that TGF-β1 acts as a crucial regulator of cell growth, proliferation, differentiation and apoptosis \[[@R2]--[@R4]\]. Epidemiologic studies have observed a significant higher concentration of circulating TGF-β1 in patients with cancer at many sites including the liver than in cancer-free controls \[[@R5]--[@R7]\]. It is hence reasonable to assume that elevated circulating TGF-β1 may be causally associated with an increased risk of developing hepatocellular carcinoma \[[@R8]\]. Determining the answer to this assumption is far from an easy proposition, but the introduction of Mendelian randomization (MR) may cast a new light on the cause-and-effect dissection using observational data.

In theory, MR means the usage of a genetic alteration as an instrument to dissect a causal effect of an intermediate phenotype on a disease and importantly this effect is not subject to reverse causation and confounding that often confuse the interpretation of observational findings \[[@R9], [@R10]\]. An immediate and direct approach for instrument selection revolves around the functional variation of encoded or relevant gene for the intermediate phenotype of interest \[[@R11], [@R12]\]. In humans, TGF-β1 is encoded by *TGFB1* gene (Gene ID: 7040) that is mapped on chromosome 19q13.1 and contains 7 exons. Experimental evidence lends support to the observation that *TGFB1* gene is frequently up-regulated in tumor cells and the loss of TGF-β signaling is proposed as a hallmark of carcinogenesis \[[@R13]--[@R15]\]. *TGFB1* gene is polymorphic in genomic sequences and it incorporates approximate 1700 validated bi-allelic polymorphisms. One of the most widely-evaluated polymorphisms is C-509T (rs1800469) in the promoter region of *TGFB1* gene and this polymorphism was reported to be associated with the significant changes of circulating TGF-β1 by many investigators \[[@R16], [@R17]\]. What\'s more, experimental evidence from reporter constructs suggested that expression of *TGFB1* gene differed significantly between the -509C allele and the -509T allele, and this difference may be caused by selective activator protein 1 (AP1) recruitment to its promoter \[[@R18]\]. To explore the possible causal association between circulating TGF-β1 and hepatocellular carcinoma, we thereby chose *TGFB1* gene C-509T polymorphism as an instrument and conducted a meta-analysis of available published studies under the principles of MR method.

RESULTS {#s2}
=======

Qualified studies {#s2_1}
-----------------

Using the predefined inclusion criteria, 10 out of 86 retrieved articles were qualified for analysis \[[@R7], [@R16], [@R17], [@R19]--[@R25]\] and the selection process is schematized in Figure [1](#F1){ref-type="fig"}. As two articles from within included sub-studies according to the co-infection of hepatitis B and C viruses \[[@R16], [@R17]\], a total of 12 studies were qualified for the association of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma, involving 2809 patients with hepatocellular carcinoma and 4802 cancer-free controls. The basic characteristics of the 12 qualified studies are shown in Table [1](#T1){ref-type="table"}. As for the association of C-509T polymorphism with circulating TGF-β1, there were 4 articles \[[@R7], [@R16], [@R17], [@R25]\] involving 10 independent comparisons and 1986 study subjects. The distributions of circulating TGF-β1 across C-509T genotypes are summarized in Table [2](#T2){ref-type="table"}.

![The selection process of qualified articles in this meta-analysis](oncotarget-07-84695-g001){#F1}

###### The baseline characteristics of 12 qualified studies in this meta-analysis

  Author (year)    Country   Source       Genotyping   Sample size   Age (yrs)   Males   HCV    HBV     Patients   Controls                                                         
  ---------------- --------- ------------ ------------ ------------- ----------- ------- ------ ------- ---------- ---------- ------- ------- ------- ----- ----- ----- ----- ----- -----
  Wan (2015)       S.China   Population   Chip         214           214         34.5    NA     0.72    NA         NA         NA      0.182   0.07    101   88    25    72    97    45
  Ma (2015)        N.China   Population   RFLP         234           375         NA      NA     0.769   0.749      0          0       NA      NA      42    101   91    71    161   143
  Ma (2015)        N.China   Population   RFLP         159           375         NA      NA     0.73    0.749      1          0       NA      NA      42    67    50    71    161   143
  Yang (2012)      S.China   Hospital     Chip         772           852         NA      NA     0.807   0.779      NA         NA      0.786   0.306   109   360   303   118   384   350
  Xin (2012)       N.China   Hospital     Chip         347           881         54.5    39.4   0.816   0.768      0          0       1       0       88    177   82    237   432   212
  Shi (2012)       S.China   Hospital     RFLP         73            117         NA      NA     0.625   0.632      NA         NA      NA      NA      8     24    40    9     55    53
  Radwan (2012)    Egypt     Population   RFLP         128           160         59.3    58.9   0.469   0.563      1          0       NA      NA      40    64    24    30    68    62
  Miki (2011)      Japan     Hospital     Chip         212           765         66      65     0.764   0.531      1          1       0       0       59    107   46    194   379   192
  Qi (2009)        S.China   Hospital     RFLP         379           299         58      55     0.654   0.719      0          0       1       0       92    198   89    93    156   50
  Qi (2009)        S.China   Hospital     RFLP         379           196         55      56     0.654   0.73       0          0       1       1       92    198   89    64    101   31
  Falleti (2008)   Italy     Population   RFLP         54            134         54      51     0.718   0.657      0.463      0.463   0.122   0.122   17    23    14    36    62    36
  Kim (2003)       Korea     Hospital     Chip         237           809         55.6    49     0.814   0.739      0          0       1       1       18    134   76    99    487   187

***NOTE*:** S.China, south China; N.China, north China; HCV, hepatitis C virus; HBV, hepatitis B virus; RFLP, restricted fragment length polymorphism.

###### The distributions of circulating TGF-β1 across *TGFB1* gene C-509T genotypes

  Author (year)   Study subjects                   Method for TGF-β1   -509TT   -509TC   -509CC                                       
  --------------- -------------------------------- ------------------- -------- -------- -------- ----- ------- ------- ----- ------- -------
  Wan (2015)      both HCC patients and controls   NA                  173      39.45    7.45     185   26.33   13.65   70    26.25   13.56
  Ma (2015)       controls                         ELISA               71       4        1.5      161   3.6     1.2     143   3.3     1
  Ma (2015)       HCC patients w/o HCV             ELISA               42       17.1     4.1      101   16.5    3.7     91    15.2    3.1
  Ma (2015)       HCC patients w/h HCV             ELISA               42       23.1     4.4      67    21.8    3.7     50    20.3    3.3
  Radwan (2012)   controls                         ELISA               30       3.9      1.1      68    3.5     0.7     62    3.2     0.95
  Radwan (2012)   cirrhosis patients with HCV      ELISA               44       15.5     2.8      74    14.6    2.1     34    13.4    2.6
  Radwan (2012)   HCC patients with HCV            ELISA               40       20.5     3.3      64    19.5    1.8     24    18.3    2.2
  Qi (2009)       controls                         ELISA               42       10.13    4.19     54    9.64    4.51    24    10.43   5.54
  Qi (2009)       HBV patients w/o HCC             ELISA               35       9.46     7.62     37    10.04   4.89    22    11.86   7.81
  Qi (2009)       HCC patients w/t HBV             ELISA               36       8.98     5.8      74    9.75    6.36    26    12.83   8.72

***NOTE***: s.d., standard deviation; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ELISA, enzyme-linked immunosorbent assay; NA, not available.

Study characteristics {#s2_2}
---------------------

All qualified articles were published from the year 2003 to 2015 and total sample size ranged from 188 to 1624. Of 12 studies, 8 were performed in China (5 in southern China and 3 in northern China), 1 separately in Japan, South Korea, Italy and Egypt. Seven studies collected cancer-free controls from hospitals and five from general populations. The C-509T genotypes were determined by restricted fragment length polymorphism (RFLP) method in 7 studies and by chip-related methods in 5 studies. Eight studies had a total sample size of at least 500 and four studies of less than 500.

C-509T polymorphism and hepatocellular carcinoma {#s2_3}
------------------------------------------------

In overall analysis, C-509T polymorphism was not significantly associated with hepatocellular carcinoma under four genetic models (Figure [2](#F2){ref-type="fig"}) and this association was obsessed by significant heterogeneity (*I*^2^ \> 50%). However, it was unlikely for the existence of publication bias as revealed by Egger\'s tests and filled funnel plots (Figure [3](#F3){ref-type="fig"}).

![Forest plots of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma\
OR: odds ratio; 95% CI: 95% confidence interval. The x-axis represents the risk estimate OR.](oncotarget-07-84695-g002){#F2}

![Funnel plots of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma](oncotarget-07-84695-g003){#F3}

To identify possible sources of clinical heterogeneity, subgroups by country, source of controls, genotype method and sample size were conducted and effect-size estimates are presented in Table [3](#T3){ref-type="table"}. Significant association was observed in studies with population-based controls under allelic (OR, 95% CI, *P*: 1.35, 1.05--1.74, 0.021), homozygous-genotype (OR, 95% CI, *P*: 1.74, 1.08--2.80, 0.023) and dominant (OR, 95% CI, *P*: 1.48, 1.01--2.17, 0.047) models, with significant statistical heterogeneity. Additionally, in studies with a total sample size of less than 500, carriers of the -509TT genotype vis-à-vis the -509CC genotype were 2.07-times more likely to develop hepatocellular carcinoma (OR, 95% CI, *P*: 2.07; 1.26--3.41; 0.004) and heterogeneity was improved (*I*^2^ = 42.8%).

###### Subgroup analysis of TGFB1 gene C-509T polymorphism with hepatocellular carcinoma

  Group                Number of studies   T vs. C                           TT vs. CC                         TC vs. CC                         TT+TC vs. CC              
  -------------------- ------------------- ------------------------- ------- ------------------------- ------- ------------------------- ------- ------------------------- -------
  Sample size                                                                                                                                                              
  ≥ 500                8                   0.94, 0.82--1.08, 0.373   71.1%   0.86, 0.64--1.15, 0.311   72.0%   0.94, 0.80--1.10, 0.447   42.2%   0.92, 0.76--1.11, 0.382   64.3%
  \< 500               4                   1.36, 0.97--1.91, 0.075   70.2%   2.07, 1.26--3.41, 0.004   42.8%   1.24, 0.66--2.33, 0.509   75.0%   1.42, 0.75--2.70, 0.282   78.8%
  Country                                                                                                                                                                  
  S.China              5                   0.96, 0.73--1.25, 0.754   84.1%   0.95, 0.55--1.64, 0.857   82.7%   0.89, 0.65--1.22, 0.450   64.1%   0.90, 0.61--1.31, 0.567   77.7%
  N.China              3                   1.07, 0.88--1.28, 0.530   53.2%   1.12, 0.79--1.59, 0.535   49.1%   1.06, 0.87--1.31, 0.562   0.0%    1.07, 0.89--1.30, 0.475   0.0%
  Source of controls                                                                                                                                                       
  Hospital             7                   0.89, 0.78--1.02, 0.100   65.4%   0.79, 0.58--1.08, 0.135   67.8%   0.87, 0.71--1.06, 0.171   54.4%   0.84, 0.67--1.05, 0.119   65.4%
  Population           5                   1.35, 1.05--1.74, 0.021   72.5%   1.74, 1.08--2.80, 0.023   69.6%   1.33, 0.96--1.84, 0.092   50.2%   1.48, 1.01--2.17, 0.047   68.9%
  Genotyping                                                                                                                                                               
  Chip                 5                   1.06, 0.87--1.29, 0.592   80.1%   1.08, 0.72--1.62, 0.722   78.5%   1.04, 0.83--1.31, 0.744   58.0%   1.07, 0.81--1.41, 0.646   74.4%
  RFLP                 7                   1.03, 0.80--1.33, 0.824   81.8%   1.09, 0.65--1.80, 0.749   80.7%   0.96, 0.70--1.32, 0.786   65.3%   0.99, 0.69--1.43, 0.954   77.1%

***NOTE***: OR, odds ratio; 95% CI, 95% confidence interval; S.China, south China; N.China, north China; RFLP, restricted fragment length polymorphism.

After modeling age, gender and the percentages of hepatitis B and C virus infection in meta-regression analysis, we failed to detect any significance of these confounding factors under four genetic models (*P* \> 0.05).

C-509T polymorphism and circulating TGF-β1 {#s2_4}
------------------------------------------

Taking the -509CC genotype as a reference, carriers of the -509TT genotype (WMD, 95% CI, *P*: 1.72 ng/ml, 0.67--2.78 ng/ml, 0.001), the -509TC genotype (WMD, 95% CI, *P*: 0.59 ng/ml, 0.21--0.98 ng/ml, 0.003) and the -509TT/-509TC genotypes (WMD, 95% CI, *P*: 0.98 ng/ml, 0.43--1.53 ng/ml, \< 0.001) had significant higher concentrations of circulating TGF-β1 in a random-effects model (Figure [4](#F4){ref-type="fig"}). However, heterogeneity was still an obsessing issue.

![Forest plots of *TGFB1* gene C-509T polymorphism with circulating TGF-β1 changes\
WMD: weighted mean difference; 95% CI: 95% confidence interval.](oncotarget-07-84695-g004){#F4}

MR analysis {#s2_5}
-----------

In view of the prerequisites for MR, causal relevance was only estimated in studies with population-based controls under homozygous-genotype and dominant models. Per unit increase in circulating TGF-β1 was significantly and causally associated with a 38% (OR, 95 CI: 1.38, 1.03--4.65) and 49% (OR, 95 CI: 1.49, 1.01--6.06) increased risk of having hepatocellular carcinoma under homozygous-genotype and dominant models, respectively.

DISCUSSION {#s3}
==========

This meta-analysis was designed to explore the causal association between circulating TGF-β1 and hepatocellular carcinoma by choosing *TGFB1* gene C-509T polymorphism as an instrument under the principles of MR method. Our findings provided evidence for the significant association of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma in population-based studies and circulating TGF-β1 changes, and importantly enhanced circulating TGF-β1 was suggested to be causally associated with an increased risk of hepatocellular carcinoma. To the best of our knowledge, this is the first report that has explored the cause-and-effect relationship between circulating TGF-β1 and hepatocellular carcinoma.

Hepatocellular carcinoma is the most common type of liver cancer and its incidence is soaring to endemic proportions, especially in Asian and African countries \[[@R26]\]. The incidence rate of hepatocellular carcinoma stems mainly from several risk factors, including gender, race/ethnicity, chronic viral hepatitis and alcoholism \[[@R27], [@R28]\]. There is also compelling evidence for genetic predisposition to hepatocellular carcinoma and *TGFB1* gene is one of promising candidates \[[@R29], [@R30]\]. Current literature is proliferating with a large volume of findings highlighting the susceptible role of *TGFB1* gene in hepatocellular carcinoma; however, there is little published knowledge revolving the genetic determinants of circulating TGF-β1 and their possible relationship with this disease. To fill this gap in knowledge, we introduced the concept of MR in this meta-analysis and produced convincing estimates for the possible causal involvement of circulating TGF-β1 in hepatocellular carcinogenesis by means of a well-defined promoter polymorphism in *TGFB1* gene as an instrument.

Although overall analysis failed to show any significance between *TGFB1* gene C-509T polymorphism and hepatocellular carcinoma, our subgroup analysis demonstrated that carriers of the -509TT genotype or the -509T allele vis-à-vis the -509CC genotype who had higher concentrations of circulating TGF-β1 were at a significantly increased risk in studies with population-based controls. Under the principles of MR, we propose for the first time the causal involvement of circulating TGF-β1 in the development of hepatocellular carcinoma. This involvement may be biologically plausible. Generally, there are two possible mechanisms for the involvement of TGF-β signaling in hepatocellular carcinoma, via intrinsically acting as an autocrine or paracrine growth factors and via extrinsically altering cancer-related microenvironments \[[@R31], [@R32]\]. A previous study has suggested that both circulating TGF-β1 and its mRNA levels can be used as sensitive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma \[[@R33]\]. A more recent study further demonstrated that TGF-β1 expression was a reliable biomarker for predicting survival in patients with hepatocellular carcinoma after hepatic resection \[[@R34]\]. In addition, an animal study confirmed that activated TGF-β pathway underlay a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma \[[@R35]\]. However, a key caveat should be raised as enhanced TGF-β1 in circulation might merely be a surrogate indicator of enhanced secretion of TGF-β1 by stromal cells via a paracrine activity, and the cross-talk between tumor cells and host stroma is reported to play a key role in carcinogenesis \[[@R31], [@R32]\]. There is indirect evidence supporting this claim that in patients with hepatocellular carcinoma, carriers of the -509CC genotype had statistically significant higher levels of circulating TGF-β1 and liver tumor tissue TGF-β1 mRNA expression compared with those with the -509TT genotype \[[@R17]\]. Exploring the correlation between circulating and stroma-secreted TGF-β1 is worthwhile, but is beyond the scope of this study. Nevertheless, on the basis of above independent lines of evidence and our current findings, circulating TGF-β1 can be exploited in clinical practice as a possible causal biomarker or a surrogate indicator of stroma-secreted TGF-β1 for the detection, diagnosis and prognosis of hepatocellular carcinoma.

Despite the promising results of this study, we must draw special attention to the MR method adopted in this meta-analysis. It is widely believed that testing for a cause-and-effect of a phenotype on a disease by testing an association between a genetic locus and the disease is reasonable and straightforward pending three key assumptions for a genetic locus quantified as an instrument variable, that is, the locus (i) should be robustly associated the phenotype, (ii) should not be associated with confounding factors that may bias the association between the phenotype and the disease and (iii) should exert its impact on the clinical outcome through the specific phenotype \[[@R36]\]. For the first assumption, the biological plausibility of *TGFB1* gene C-509T polymorphism is well defined, as this polymorphism is reported to account for a nearly twofold difference in circulating TGF-β1, which might be due to transcriptional suppression by the binding of activator protein 1 to this locus \[[@R18]\]. In addition, as this meta-analysis is not based on individual participant data and some necessary data are missing, it is beyond our ability to test the justification of the last two assumptions for the genetic instrument selected. Furthermore, the presence of linkage disequilibrium, genetic heterogeneity, pleiotropy, population stratification, canalization, or lack of knowledge about the confounding factors deserves special consideration when interpreting the causal effect in MR analysis \[[@R9], [@R37]\].

Finally, when interpreting these finding, several potential limitations of this MR meta-analysis should be considered. The first limitation was the retrieval of only English-language articles, which might result in a selection bias. However, this bias is unlikely to affect the validity of our findings because our Egger\'s tests and filled funnel plots suggested a low probability of publication bias. The second limitation might be inadequate study power in view of limited qualified studies and small sample sizes involved and this limitation became more obvious in some subgroup analyses. The third limitation was that although statistical heterogeneity was improved in some subgroups, other sources of clinical heterogeneity remained to be resolved. The fourth limitation lied in the incapability to justify some prerequisites of the MR method due to the unavailability of original data from each qualified study. The fifth limitation was that only one promoter polymorphism in *TGFB1* gene was selected as an instrument and it is encouraging to see whether this polymorphism in combination with another functional locus will enhance risk prediction for hepatocellular carcinoma.

In conclusion, our findings provide evidence for the significant association of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma in population-based studies and circulating TGF-β1 changes, and importantly enhanced circulating TGF-β1 was suggested to be causally associated with an increased risk of hepatocellular carcinoma by choosing *TGFB1* gene C-509T polymorphism as an instrument, the association warranting further validation in large, independent studies. Considering the ubiquity of genetic heterogeneity and in view of sample sizes involved, our findings should be viewed to be preliminary until further confirmation in future larger, well-designed studies.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

The Medline (<http://www.ncbi.nlm.nih.gov/pubmed/>) and Embase (<http://store.elsevier.com/embase>) were searched to identify articles that examined the association of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma and/or TGF-β1 changes in circulation before July 2016. Key terms included ("hepatocellular carcinoma" or "hepatocellular cancer" or "liver cancer" in title) and ("transforming growth factor beta" or "TGFB" or "TGFbeta" or "TGF-beta" in abstract) and ("genotype" or "allele" or "polymorphism" or "variant" or "mutation" in abstract). All retrieved articles were managed by the EndNote X7 software (Thomson Reuters EndNote). For major reviews, meta-analyses and original investigations, we also checked the bibliographies to avoid possible missing articles. The implementation of this meta-analysis abides by the guidelines in the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@R38]\].

Inclusion criteria {#s4_2}
------------------

Articles that examined the association of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma and/or TGF-β1 changes in circulation were included pending sufficient information to deduct odds ratio (OR) and weighted mean difference (WMD), as well as their 95% confidence interval (95% CI). Moreover, only articles published in English language were taken into account. Additionally, source of study participants must be described clearly in each study.

Data collection {#s4_3}
---------------

From each article, necessary data were collected and typed into a standard form separately by two authors (Wei-Qun LU and Ji-Liang QIU) and after cross-checking, disagreements were resolved by consensus. Necessary data incorporated the first author\'s surname name, year of publication, country, source of controls, genotyping platform, matching status, sample size, the genotype counts of *TGFB1* gene C-509T polymorphism or/and the mean and standard deviation values of circulating TGF-β1 across C-509T three genotypes and if available age, gender composition and the percentages of hepatitis B and C virus infection.

Statistical analysis {#s4_4}
--------------------

The risk prediction of *TGFB1* gene C-509T polymorphism for hepatocellular carcinoma was measured by the ORs with 95% CIs in a random-effects model using the DerSimonian/Laird method \[[@R39]\]. The mean changes of circulating TGF-β1 across genotypes were measured by the WMDs with 95% CIs.

Statistical heterogeneity between studies was measured by inconsistency index (*I*^2^). The *I*^2^ represents the percentage of observed diversity resulting from heterogeneity rather than from chance. Higgins et al suggested an *I*^2^ of 50% or over as significant heterogeneity \[[@R40]\]. Besides statistical heterogeneity, clinical evidence of heterogeneity is also no less important and it is usually evaluated by subgroup analysis and meta-regression analysis. In this meta-analysis, subgroup analysis was performed according to country, source of controls, genotype method and sample size, respectively. Meta-regression analysis was performed by modeling age, gender and the percentages of hepatitis B and C virus infection individually.

It is widely accepted that any study with a significant and positive result tends to receive more favorable publication decisions than the equally well-conducted study with a nonsignificant and negative result, the phenomenon known as publication bias \[[@R41]\]. Several criteria have been developed to quantify the probability of publication bias and in this meta-analysis Egger\'s test and filled funnel plot were adopted to judge this bias. The significance level of Egger\'s test is set at 10%, a commonly held cutoff value.

On the premise of the significant association of *TGFB1* gene C-509T polymorphism with hepatocellular carcinoma and circulating TGF-β1 changes, the MR method is used accordingly to infer the cause-and-effect relationship. Under the principles of MR put forwarded by Katan MB in 1986 \[[@R42]\], the causal risk prediction of circulating TGF-β1 for hepatocellular carcinoma was calculated as the ratio of the coefficient of the association between *TGFB1* gene C-509T polymorphism and hepatocellular carcinoma to the ratio of the coefficient of the association between this polymorphism and circulating TGF-β1 changes. In detail, suppose that OR~TT-vs-CC~ is the risk estimate of the -509TT genotype vis-à-vis the -509CC genotype for hepatocellular carcinoma and ΔP is the mean difference in circulating TGF-β1 between the -509TT genotype and the -509CC genotype, and then the causal estimate of circulating TGF-β1 for hepatocellular carcinoma is calculated as OR~TT-vs-CC~ ^k/ΔP^ for per k change in TGF-β1 \[[@R43]\].

All statistical calculations aforementioned were done with Stata software version 12.0 for Windows (StataCorp, College Station, Texas, USA).
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